Compounding, Drug Development and Immunity

STAT+: Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

STAT

JANUARY 22, 2025

Immune checkpoint inhibitors, drugs that can help make the immune system recognize and destroy cancer more aggressively, are one of the most important medicines in cancer treatment today.

Immunity

Immunity Immunization Compounding Drug Development

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds.

Compounding

Compounding Immunity Immunization Drug Development

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

European Pharmaceutical Review

DECEMBER 16, 2022

According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 FMI stated drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations.

Compounding

Compounding Immunity Immunization Drug Development

The future of medical cannabis development in Europe

European Pharmaceutical Review

JULY 13, 2023

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.

Compounding

Compounding Drug Development Clinical Pharmacology Documentation

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

DECEMBER 5, 2022

Despite this, the medical use of cannabinoid drugs is heavily restricted, including being banned in 137 countries, according to the United Nations. Cannabinoid-based drugs are derived from compounds found in the cannabis plant. Cannabinoid receptors fall into two categories: CB1 and CB2 receptors.

Controlled Substances

Controlled Substances Compounding Immunity Immunization

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Pharmaceutical Technology

AUGUST 12, 2022

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4

Immunity

Immunity Immunization Chemotherapy Compounding

Lilly cuts a $960m deal with Rigel on RIP kinase

pharmaphorum

FEBRUARY 19, 2021

Rigel’s clinical-stage R552 is the main asset in the deal – which also includes $835 million in development, regulatory, and commercial milestones – but Lilly has also taken rights to preclinical-stage follow-ups that can cross into the brain and may have potential in central nervous system disorders.

Compounding

Compounding Immunity Immunization Drug Development

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.

Dosage

Dosage Chemotherapy Compounding Immunity

Empress Therapeutics emerges with $50m to fund small molecule development

Pharmaceutical Technology

JUNE 21, 2023

Life sciences venture capital firm Flagship Pioneering has unveiled Empress Therapeutics, a small molecule drug development startup. This will support development of its proprietary Chemilogics platform and drug discovery pipeline. So far, Empress claims to have generated 15 drug leads across multiple indications.

Compounding

Compounding Communication Immunity Immunization

Innovating bioanalysis to advance oligonucleotide therapeutics

European Pharmaceutical Review

FEBRUARY 13, 2025

As drug developers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Finally, oligo metabolites often share similar structures and molecular weights with parent compounds, leading to potential interference during analysis.

Compounding

Compounding Immunity Immunization Drug Development

Getting on with Rare Disease Therapeutic Options (Orphan Disease Therapies)

PharmaShots

MARCH 14, 2023

The article focuses on challenges faced in drug development, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drug development plan Drug development plans for rare diseases can be circuitous, resulting in fewer participation from companies.

Drug Development

Drug Development Immunity Immunization Compounding

Clearing the air on liposomes and LNPs in drug delivery

Express Pharma

APRIL 4, 2024

Advantages of lipids and essential factors in selection Lipid-based formulations play a pivotal role in drug discovery and delivery, enhancing bioavailability by controlling therapeutic compounds’ solubility, permeability, absorption, distribution, and metabolism.

Vaccines

Vaccines Compounding Immunity Immunization

COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccines

Vaccines Drug Pricing Compounding Immunity

Delivery systems for biologics

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 Anna has a medical degree and a postgraduate degree in healthcare management and is an expert in all stages of drug development. percent through 2027.

Vaccines

Vaccines Immunity Immunization Compounding

Pharmacist Digest

STAT+: Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

GSK partners LifeMine on fungi-derived medicines

Trending Sources

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

The future of medical cannabis development in Europe

Cannabinoids receptors: popular preclinical target but banned in 137 countries

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Lilly cuts a $960m deal with Rigel on RIP kinase

PROTAC development gains momentum, but clinical performance is poor

Empress Therapeutics emerges with $50m to fund small molecule development

Innovating bioanalysis to advance oligonucleotide therapeutics

Getting on with Rare Disease Therapeutic Options (Orphan Disease Therapies)

Clearing the air on liposomes and LNPs in drug delivery

COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts

Delivery systems for biologics

Stay Connected